lapatinib / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

15 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lapatinib / Generic mfg.
LOGiC, NCT00680901 / 2007-005725-29: - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Checkmark ESMO 2013
Sep 2013 - Sep 2013: ESMO 2013
Checkmark ASCO-2013
Jun 2013 - Jun 2013: ASCO-2013
Checkmark For advanced HER2-positive gastric cancer
More
Active, not recruiting
3
545
Europe, Canada, US, RoW
Lapatinib, Tykerb, Tyverb, Placebo, Capecitabine, Oxaliplatin
Novartis Pharmaceuticals
Neoplasms, Gastrointestinal Tract
09/12
01/25
CALGB-40601, NCT00770809: Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark ASCO 2013
More
Active, not recruiting
3
305
US
Laboratory Biomarker Analysis, Lapatinib Ditosylate, Tykerb, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Trastuzumab, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herclon, Hertraz, Herzuma, Kanjinti, Ogivri, Ontruzant, PF-05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera
National Cancer Institute (NCI)
Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
01/14
07/24
CTRIAL-IE (ICORG) 11-10, NCT01526369: A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer

Completed
3
75
Europe, RoW
Trastuzumab, Paclitaxel, Lapatinib
Cancer Trials Ireland
Metastatic Breast Cancer
11/15
02/23
EPHOS-B, NCT01104571 / 2008-005466-30: Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer

Checkmark P3 trial design
Dec 2011 - Dec 2011: P3 trial design
Active, not recruiting
3
257
Europe
trastuzumab, lapatinib ditosylate, laboratory biomarker analysis, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery
Institute of Cancer Research, United Kingdom, University of Manchester, Manchester University NHS Foundation Trust, Cancer Research UK, Novartis
Breast Cancer
08/17
09/25
BO29919, NCT03084939: Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

Completed
3
351
RoW
Trastuzumab Emtansine, Kadcyla, Lapatinib, Capecitabine
Hoffmann-La Roche
Breast Cancer
11/18
03/23
2017-002851-27: GENETIC SEQUENCING FOR THE TREATMENT OF ADVANCED SOFT-TISSUE SARCOMAS SEQUENCAGE GENETIQUE POUR LE TRAITEMENT DES SARCOMES DES TISSUS MOUS

Not yet recruiting
3
960
Europe
CAPMATINIB, OLAPARIB, DURVALUMAB, GLASDEGIB, TAS-120, INC280, AZD2281, MEDI4736, PF-04449913, TAS-120, Capsule, hard, Film-coated tablet, Concentrate for solution for infusion, Tablet, TASIGNA, ZYKADIA, TYVERB, MEKINIST, TAFINLAR, LYNPARZA, IBRANCE
INSERM, Institut National du Cancer (INCa)
Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcoma, Adult patients with advanced soft-tissue sarcoma, Diseases [C] - Cancer [C04]
 
 
TULIP, NCT03262935 / 2017-001994-18: SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Completed
3
437
Europe, Canada, US, RoW
(vic-)trastuzumab duocarmazine, SYD985, Trastuzumab vc-seco-DUBA, Physician's choice, Lapatinib (Lap), Capecitabine (Cap), Trastuzumab (T), Vinorelbine (Vino), Eribulin (Eri)
Byondis B.V.
Metastatic Breast Cancer
03/21
06/22
ChiCTR1900027887: A clinical study for evaluating the efficacy and safety of BAT8001 injection for the treatment of HER2-positive advanced breast cancer

Recruiting
3
410
 
3.6 mg/kg, q3w, administered intravenously ;Lapatinib dose: Qd, 1250 mg/dose, administered on days 1-21 of each cycle; Capecitabine dose: Bid, 1000 mg/m2, administered on days 1-14 of each cycle, rest on days 15-21.
Sun Yat-sen University Cancer Center; Bio-thera Solutions, Ltd., Self-raised funds
HER-2 positive advanced breast cancer
 
 
NCT06313983: A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer

Recruiting
3
339
RoW
Hemay022+AI, Lapatinib+Capecitabine
Tianjin Hemay Pharmaceutical Co., Ltd
Breast Cancer
12/25
06/26
DESTINY-Breast02, NCT03523585 / 2018-000221-31: DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread []

Hourglass Jan 2023 - Jun 2023 : Acceptance of regulatory submission for HER2 breast cancer (based on DESTINY-Breast02 trial)
Hourglass Jan 2022 - Dec 2022 : Acceptance of regulatory submission in US for pre-treated HER2 breast cancer (based on DESTINY-Breast02 trial)
Checkmark Data from DESTINY-Breast02 trial for HER2-positive, unresectable and/or metastatic breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Data from DESTINY-Breast02 trial for HER2-positive, unresectable and/or metastatic breast cancer at SABCS 2022
Checkmark Presentation of primary data from DESTINY-Breast02 trial for HER2 +ve breast cancer
More
Active, not recruiting
3
608
Europe, Japan, US, RoW
Trastuzumab deruxtecan, DS-8201a, T-DXd, Capecitabine, Investigator's Choice Comparative Therapy, Lapatinib, Trastuzumab
Daiichi Sankyo, Daiichi Sankyo Co., Ltd., AstraZeneca
Breast Cancer
06/22
05/25
CTR20200806: Phase III study of TAA013 versus lapatinib combined with capecitabine in patients with HER2-positive breast cancer

Terminated
3
438
China
TAA013 - TOT Biopharm
Dong Yao Pharmaceutical Co., Ltd.
Locally advanced or metastatic HER2-positive breast cancer
 
 
MULTISARC, NCT03784014: Molecular Profiling of Advanced Soft-tissue Sarcomas

Active, not recruiting
3
603
Europe
Nilotinib, TASIGNA, Ceritinib, ZYKADIA, Capmatinib, Lapatinib, TYVERB, Trametinib, MEKINIST, Trametinib and Dabrafenib, MEKINIST and TAFINLAR, Olaparib and Durvalumab, LYNPARZA, MEDI4736, Palbociclib, IBRANCE, PD-0332991, Glasdegib, PF-04449913, TAS-120, Next Generation sequencing exome, RNA Seq, NGS, High throughput sequencing
Institut National de la Santé Et de la Recherche Médicale, France, Commissariat A L'energie Atomique, Institut Bergonié, Plateforme labellisée Inca - Institut Bergonié, Bordeaux, Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris, EUCLID Clinical Trial Platform
Soft Tissue Sarcoma
12/23
10/25
Fillful-03, NCT05122494: A Phase Ⅲ Study of the Efficacy and Safety of Hemay022+Aromatase Inhibitor(AI) in Participants With ER+/HER2+ Advanced or Metastatic Breast Cancer

Recruiting
3
339
RoW
Hemay022+AI, Lapatinib+Capecitabine
Tianjin Hemay Oncology Pharmaceutical Co., Ltd
Breast Cancer
02/24
06/24
ACE-Breast-02, CTR20201708: Clinical study evaluating ARX788 in the treatment of HER2-positive advanced breast cancer

Recruiting
2/3
440
China
capecitabine - Generic mfg., lapatinib - Generic mfg., anvatabart opadotin (ARX788) - Ambrx
Zhejiang Pharmaceutical Co., Ltd./Zhejiang Xinma Biopharmaceutical Co., Ltd.
HER2-positive breast cancer
 
 
NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting
2/3
301
RoW
RC48-ADC, RC48, Lapatinib, Capecitabine
RemeGen Co., Ltd.
Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases
07/24
12/24

Download Options